For example, phosphosites/peptides derived from ALK and FGFR were only detected in lung adenocarcinoma (LUAD) cell line H3122 (driven by ALK fusion) and bladder carcinoma cell line RT112 (driven by FGFR3 fusion), respectively, while in another LUAD cell line PC9, which harbors an activating EGFR mutation (exon 19 deletion) higher levels of EGFR phosphosites were detected. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.